Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

The paracrine hormone hypothesis of colorectal cancer.

Pitari GM, Li P, Lin JE, Zuzga D, Gibbons AV, Snook AE, Schulz S, Waldman SA.

Clin Pharmacol Ther. 2007 Oct;82(4):441-7. Review.

PMID:
17687268
2.

Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.

Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari GM, Waldman SA.

Gastroenterology. 2007 Aug;133(2):599-607.

PMID:
17681179
3.
4.

Can colorectal cancer be prevented or treated by oral hormone replacement therapy?

Li P, Lin JE, Schulz S, Pitari GM, Waldman SA.

Curr Mol Pharmacol. 2009 Nov;2(3):285-92. Review.

5.

Human colon cancer stem cells: a new paradigm in gastrointestinal oncology.

Boman BM, Huang E.

J Clin Oncol. 2008 Jun 10;26(17):2828-38. doi: 10.1200/JCO.2008.17.6941. Review.

PMID:
18539961
6.

GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Li P, Lin JE, Marszlowicz GP, Valentino MA, Chang C, Schulz S, Pitari GM, Waldman SA.

Drug News Perspect. 2009 Jul-Aug;22(6):313-8. doi: 10.1358/dnp.2009.22.6.1395254. Review.

7.

Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.

Gibbons AV, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S, Snook AE, Schulz S, Waldman SA.

Cancer Res. 2013 Nov 15;73(22):6654-66. doi: 10.1158/0008-5472.CAN-13-0887.

8.

Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.

Lin JE, Li P, Pitari GM, Schulz S, Waldman SA.

Future Oncol. 2009 May;5(4):509-22. doi: 10.2217/fon.09.14. Review.

9.

Sex modulates intestinal transformation by the tumor-suppressor GCC.

Li P, Schulz S, Pitari GM, Waldman SA.

Clin Transl Sci. 2008 Sep;1(2):146-50. doi: 10.1111/j.1752-8062.2008.00029.x.

10.

Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy.

Li P, Lin JE, Snook AE, Gibbons AV, Zuzga DS, Schulz S, Pitari GM, Waldman SA.

Clin Transl Sci. 2008 Sep;1(2):163-7. doi: 10.1111/j.1752-8062.2008.00040.x.

11.

Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level.

Macartney-Coxson DP, Hood KA, Shi HJ, Ward T, Wiles A, O'Connor R, Hall DA, Lea RA, Royds JA, Stubbs RS, Rooker S.

BMC Cancer. 2008 Jul 1;8:187. doi: 10.1186/1471-2407-8-187.

12.

Overlapping expression of microRNAs in human embryonic colon and colorectal cancer.

Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez A, Balagué O, Garcia-Foncillas J.

Cell Res. 2008 Aug;18(8):823-33. doi: 10.1038/cr.2008.81.

PMID:
18607389
13.

HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer.

Ordóñez-Morán P, Dafflon C, Imajo M, Nishida E, Huelsken J.

Cancer Cell. 2015 Dec 14;28(6):815-29. doi: 10.1016/j.ccell.2015.11.001.

14.

Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen.

Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA.

Clin Pharmacol Ther. 2007 Dec;82(6):734-9. Review.

PMID:
17898707
15.

Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression.

Simiantonaki N, Taxeidis M, Jayasinghe C, Kurzik-Dumke U, Kirkpatrick CJ.

BMC Cancer. 2008 Nov 4;8:320. doi: 10.1186/1471-2407-8-320.

16.

Appearance of epithelial and stromal genomic instability in background colorectal mucosa of sporadic colorectal cancer patients: relation to age and gender.

Umeto H, Yoshida T, Araki K, Yagishita H, Mikami T, Okayasu I.

J Gastroenterol. 2009;44(10):1036-45. doi: 10.1007/s00535-009-0103-1.

PMID:
19590931
17.

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C.

Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Review.

PMID:
18718806
18.

N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.

Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruïne AP, van Engeland M.

J Natl Cancer Inst. 2009 Jul 1;101(13):916-27. doi: 10.1093/jnci/djp131.

PMID:
19535783
19.

TATA box-binding protein-associated factor 12 is important for RAS-induced transformation properties of colorectal cancer cells.

Voulgari A, Voskou S, Tora L, Davidson I, Sasazuki T, Shirasawa S, Pintzas A.

Mol Cancer Res. 2008 Jun;6(6):1071-83. doi: 10.1158/1541-7786.MCR-07-0375.

20.

Cancer stem cells: a step toward the cure.

Boman BM, Wicha MS.

J Clin Oncol. 2008 Jun 10;26(17):2795-9. doi: 10.1200/JCO.2008.17.7436. No abstract available.

PMID:
18539956

Supplemental Content

Support Center